Patents Represented by Attorney Robin S. Quartin
  • Patent number: 7270965
    Abstract: The present invention is directed to assays that can be used to screen for compounds that act as agonists or antagonists or inverse agonists of bovine adrenal medulla docosapeptide (BAM-22P). The assays are based upon the binding of BAM-22P to the rat and human DRR receptors.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: September 18, 2007
    Assignee: AstraZeneca AB
    Inventors: Sultan Ahmad, Eric Grazzini, Thierry Groblewski, Paolo Lembo, Ralf Schmidt
  • Patent number: 7078177
    Abstract: The present invention is directed to assays that can be used to screen for compounds that act as agonists or antagonists or inverse agonists of Dynorphin A and its analogues. The assays are based upon the binding of Dynorphin A and its analogues to the rat and human MAS receptors.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: July 18, 2006
    Assignee: AstraZeneca AB
    Inventors: Sultan Ahmad, Eric Grazzini, Paola Lembo
  • Patent number: 6969596
    Abstract: An isolated and purified human receptor tyrosine kinase is described. A cDNA sequence which encodes the native polypeptide is disclosed as well as the structural coding region and the amino acid residue sequence of the tyrosine kinase. Methods are provided which employ novel sequences to identify compounds that modulate the biological and/or pharmacological activity of the tyrosine kinase and hence regulate cellular and tissue physiology. Biologically-effective antisense molecules, as well as dominant negative mutant versions of the kinase, are described which are suitable for therapeutic use. The invention is also related to the diagnosis, study, prevention, and treatment of pathophysiological disorders related to or mediated by the biological molecule.
    Type: Grant
    Filed: January 7, 2002
    Date of Patent: November 29, 2005
    Assignee: AstraZeneca AB
    Inventors: Namit Ghildyal, Govindaswamy Panchamoorthy